Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market


11.02.13 11:05
Meldung
 
(Nasdaq:SGYP), a developer of new drugs to treatgastrointestinal disorders and diseases, today announced that its common stockhas been approved for listing on The NASDAQ Global Market under the symbol'SGYP.' Trading on The NASDAQ Global Market is expected to commence on February12, 2013. The Company's units and warrants will continue to trade on The NASDAQCapital Market under the symbols 'SGYPU' and 'SGYPW,' respectively. About SYNERGY PHARMACEUTICALS INC.Synergy is a biopharmaceutical company focused on the development of new drugsto treat gastrointestinal disorders and diseases. Synergy's lead proprietarydrug candidate, plecanatide, is a synthetic analog of the humangastrointestinal hormone uroguanylin, and functions by activating the guanylatecyclase C receptor on epithelial cells of the GI tract. Synergy completed apositive Phase I study of plecanatide in healthy volunteers, and positive PhaseIIa and Phase IIb/III clinical trials in patients with chronic idiopathicconstipation (CIC). Detailed positive findings from a recently completed PhaseIIb/III clinical trial will be presented at a major scientific meeting thisyear. Synergy is also developing plecanatide for the treatment of irritablebowel syndrome with constipation (IBS-C), having initiated the first trial inIBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is inclinical development to treat inflammatory bowel diseases, and has justcompleted its first Phase I trial in healthy volunteers. More information isavailable at http://www.synergypharma.com. Media Contact: Janet Skidmore Office: 215-658-4915 Mobile: 215-429-2917 skidmorecomm@earthlink.net Investor Contact: Danielle Spangler The Trout Group synergy@troutgroup.com (646) 378-2924News Source: NASDAQ OMX11.02.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.The issuer is solely responsible for the content of this announcement.DGAP's Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Media archive at www.dgap-medientreff.de and www.dgap.de--------------------------------- Language: EnglishCompany: Synergy Pharmaceuticals United StatesPhone: Fax: E-mail: Internet: ISIN: US8716393082WKN: End of Announcement DGAP News-Service ---------------------------------


 

Kurs- und weitere Informationen zum Thema:

SYNERGY PHARMACEUTICALS INC

Aktuelle Diskussionen zum Thema:


Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

SYNERGY PHARMACEUTICALS INC
Weitere Meldungen
 
11.02 Stimmrechtsanteile: ESTAVI.
11.02 Directors' Dealings: Rofin-Sin.
11.02 Cham Paper Group Holding .
11.02 Zwischenmitteilung: MAGNA.
11.02 Stimmrechtsanteile: Francoty.
11.02 Finanzbericht: Andreae-Noris .
11.02 Deutsche Rohstoff AG: Tek.
11.02 Synergy Pharmaceuticals to .
11.02 Finanzbericht: Sektkellerei Sc.
11.02 Dresdner Factoring veröffent.
11.02 Monument Mining Ltd. äußer.
11.02 Gemeinsame Auktion von ZD.
11.02 Vuzix beginnt mit der Ausli.
11.02 Joyou AG : 194 Filialeröffn.
11.02 BIOMEDICAL NYRT.: Katar .
11.02 Finanzbericht: cycos AG: Be.
11.02 ESTAVIS AG: Halbjahresbe.
11.02 euromicron auf der CeBIT 2.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: LEG Imm.
08.02 Stimmrechtsanteile: METRO .
08.02 Stimmrechtsanteile: METRO .


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 7029 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Gazprom: Die Wende?
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
DAX DOW das Hoch ist ...
Thomas Heydrich, Systemstrading.de (19:41)
Experte: Thomas Heydrich, Systemstrading.de
SJB FondsEcho. Allokation. ...
Gerd Bennewirtz, SJB FondsSkyline (18:17)
Experte: Gerd Bennewirtz, SJB FondsSkyline
Apple und Facebook – ...
Feingold-Research, (17:43)
Experte: Feingold-Research,
Märkte verarbeiten US-...
Jens Klatt, Chefanalyst von DailyFX (17:42)
Experte: Jens Klatt, Chefanalyst von DailyFX
ING (L) Invest Emerging ...
ING IM International, (16:10)
Experte: ING IM International,
S&P-500-Index - Neue ...
Christian Zoller, www.boerse-daily.de (16:01)
Experte: Christian Zoller, www.boerse-daily.de
DAX: Erneuter ...
IG Markets, (15:55)
Experte: IG Markets,
Achtung! Lufthansa-Aktie ...
Carsten Englert, (15:32)
Experte: Carsten Englert,
DAX stürzt massiv ab - ...
Berndt Ebner, Der-Trading-Coach.com (15:02)
Experte: Berndt Ebner, Der-Trading-Coach.com
Unternehmenszahlen: Bayer ...
Cornelia Frey, Börse Stuttgart AG (14:54)
Experte: Cornelia Frey, Börse Stuttgart AG
Gazprom: Die Wende?
Stefan Hofmann, STOCK-WORLD (14:22)
Experte: Stefan Hofmann, STOCK-WORLD
Hemisphere Energy - ...
Björn Junker, GOLDINVEST.de (13:37)
Experte: Björn Junker, GOLDINVEST.de
Niquet's World
Neues vom Portal
 
Deutsche FX-Broker sind im Kommen
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen